GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Konruns Pharmaceutical Co Ltd (SHSE:603590) » Definitions » Net Income (Continuing Operations)

Beijing Konruns Pharmaceutical Co (SHSE:603590) Net Income (Continuing Operations) : ¥204.6 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Beijing Konruns Pharmaceutical Co Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Beijing Konruns Pharmaceutical Co's Net Income (Continuing Operations) for the three months ended in Mar. 2024 was ¥46.8 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥204.6 Mil.


Beijing Konruns Pharmaceutical Co Net Income (Continuing Operations) Historical Data

The historical data trend for Beijing Konruns Pharmaceutical Co's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Konruns Pharmaceutical Co Net Income (Continuing Operations) Chart

Beijing Konruns Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 266.08 183.36 167.44 123.90 187.57

Beijing Konruns Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.86 73.51 59.47 24.73 46.85

Beijing Konruns Pharmaceutical Co Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥204.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beijing Konruns Pharmaceutical Co  (SHSE:603590) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.


Beijing Konruns Pharmaceutical Co Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Beijing Konruns Pharmaceutical Co's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing Konruns Pharmaceutical Co (SHSE:603590) Business Description

Traded in Other Exchanges
N/A
Address
No. 11 Xingsheng South Road, Economic Development Zone, Miyun District, Beijing, CHN
Beijing Konruns Pharmaceutical Co Ltd is a Chinese pharmaceutical company. It is engaged in the research and development of innovative drugs, and is oriented to clinical needs.
Executives
Feng Zhang Zheng Director

Beijing Konruns Pharmaceutical Co (SHSE:603590) Headlines

No Headlines